Business Context and Reporting Period
This Form 8-K was filed by Halozyme Therapeutics, Inc. on September 19, 2006. The report discloses an unregistered sale of equity securities pursuant to Item 3.02.
Key Financial Metrics
- Transaction Type: Exercise of callable Common Stock purchase warrants.
- Shares Issued: 2,204,188 shares of Common Stock ($0.001 par value).
- Price Per Share: $1.75.
- Gross Proceeds: Approximately $3.9 million.
- Investor Profile: Institutional and accredited investors.
Material Changes
The filing reports a specific capital event rather than a comparative financial period. The material change is the issuance of approximately 2.2 million shares and the receipt of $3.9 million in gross proceeds from warrant exercises. No shareholder approval was required for this transaction.
Guidance, Outlook, and Risks
The filing does not provide forward-looking guidance, management commentary on future operations, or specific risk factors beyond the standard regulatory context. The shares were sold pursuant to exemptions from registration under Regulation D of the Securities Act of 1933. A registration statement covering the resale of these shares has been previously filed with the SEC.
Investor Verification Checklist
- Verify the total number of outstanding shares post-transaction to assess dilution impact.
- Confirm the status of the previously filed registration statement for the resale of these shares.
- Review the terms of the callable warrants to understand future exercise obligations.
- Check subsequent filings for the actual use of the $3.9 million in proceeds.